8th Global Pharmacovigilance and Drug Safety Summit
|8th Global Pharmacovigilance and Drug Safety Summit|
|Place||Kuala Lumpur, Malaysia|
"The field of Pharmacovigilance is growing by and large, its development is making high impact in field of Pharmaceuticals and medical sciences. 8th Global Pharmacovigilance & Drug Safety Summit which will be held during July 8-10 in Kuala Lumpur, Malaysia, focuses on the advancements in pharmacovigilance and risk managementfocusses on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence..The main theme of 8th Global Pharmacovigilance & Drug Safety Summit is “Innovations in Pharmacovigilance for Systematic Safety and Management”."
"Conference Series LLC, the World Class Open Access Publisher and Scientific Events Organizer was hosting 8th Global Pharmacovigilance & Drug safety Summit during July 06-07, 2017 at Kuala Lumpur, Malaysia Conference Series LLC Conferences delivered new ideas, convictions, strategies, and tactics that directly affect how you do business. No other event offered a more impressive roster of keynote speakers, quality attendees and compelling content. This Conference provided a forum for exchange of ideas and authoritative views by leading scientists as well as business leaders and investors in this exciting field. Outstanding keynote speakers and well known leading scientists and experts from around the globe have been expected to share their knowledge. The event participants are typically high-level decision makers representing various parts of the industry and many participants are repeaters who know each other. This created a relaxed and informal atmosphere with the right settings for meeting new people."
Global Pharmacovigilance Market is expected to reach USD 5.51 billion by 2020, according to a new study by Grand View Research, Inc. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years. Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development.
"Global Pharmacovigilance 2017 stands for advertising of the products/services of the companies in the Medical and Healthcare sectors had been placed in the exhibition area throughout the Conference."
Target Audience: Pharmacovigilance Students, Scientists Pharmacovigilance Researchers Pharmacovigilance Faculty Medical Colleges Pharmacovigilance Associations and Societies Business Entrepreneurs Training Institutes Software developing companies Manufacturing Medical Devices Companies Data Management Companies.
- 1 Top Photos
- 2 Top Videos
- 3 “Innovations in Pharmacovigilance for Systematic Safety and Management”
- 4 Agenda
- 5 Sessions Include talks on Drug Safety, Adverse Drug Reactions, Pharmacokinetics and Pharmacodynamics, Pre-Clinical and Clinical Trials, Challenges in Pharmacovigilance, Clinical Trials on Various Disorders, Pharmacovigilance Market, Clinical Research and Statistics, Case Report in Clinical Trials, Pharmacovigilance Significance & Scope, Continental Pharmacovigilance, Good Pharmacovigilance Practice, Pharmacovigilance and Risk Management, Medical devices Pharmacovigilance, Veterinary Pharmacovigilance, Biopharmaceutics, PV Data Base Management, PV Consultings And Bussiness opportunity, Regulatory Affairs, Growth strategies in Pharma, Pharmacy Practices and its Challenges
- 6 Fun things happened
“Innovations in Pharmacovigilance for Systematic Safety and Management”
The World Health Organization (WHO) defines pharmacovigilance as the science and activities relating to the detection, evaluation, understanding, and prevention of adverse reactions to medicines or any other medicine-related problems. The definition and scope of pharmacovigilance have evolved to recognize the importance of a systems approach for monitoring and improving the safe use of medicines.1 A simpler definition describes pharmacovigilance as the processes and science of monitoring the safety of medicines and taking action to reduce risk and increase benefit.2 Therefore, the assessment of benefit versus risk must begin during the preclinical evaluation of a medicinal product and must extend throughout its full life cycle. As a result, there is now added focus on safety and risk assessment after a product has received regulatory approval, when it is placed on the market and prescribed to large populations. Although there is no international standard that dictates the components of an adequate pharmacovigilance system or the processes to be engaged in risk management, there is consensus among the major regulators that pharmacovigilance is necessary and important in the development and commercialization of medicinal products. Therefore it is essential in building capacity for clinical trials to understand the components, the functions, and the processes required for full and effective pharmacovigilance and risk management.